Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy of early chronic phase chronic myelogenous leukemia (CML) with SCH54031 (PEG interferon alpha 2B/PEG intron) and low-dose cytosine arabinoside (Ara-C).

Trial Profile

Therapy of early chronic phase chronic myelogenous leukemia (CML) with SCH54031 (PEG interferon alpha 2B/PEG intron) and low-dose cytosine arabinoside (Ara-C).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Cytarabine
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center
    • 06 Jun 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 27 Aug 2012 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top